Literature DB >> 20147631

Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation.

Jian Ding1, Aprille Rapista, Natalia Teleshova, Goar Mosoyan, Gary A Jarvis, Mary E Klotman, Theresa L Chang.   

Abstract

Sexually transmitted infections increase the likelihood of HIV-1 transmission. We investigated the effect of Neisseria gonorrheae (gonococcus [GC]) exposure on HIV replication in primary resting CD4(+) T cells, a major HIV target cell during the early stage of sexual transmission of HIV. GC and TLR2 agonists, such as peptidylglycan (PGN), Pam(3)CSK(4), and Pam(3)C-Lip, a GC-derived synthetic lipopeptide, but not TLR4 agonists including LPS or GC lipooligosaccharide enhanced HIV-1 infection of primary resting CD4(+) T cells after viral entry. Pretreatment of CD4(+) cells with PGN also promoted HIV infection. Anti-TLR2 Abs abolished the HIV enhancing effect of GC and Pam(3)C-Lip, indicating that GC-mediated enhancement of HIV infection of resting CD4(+) T cells was through TLR2. IL-2 was required for TLR2-mediated HIV enhancement. PGN and GC induced cell surface expression of T cell activation markers and HIV coreceptors, CCR5 and CXCR4. The maximal postentry HIV enhancing effect was achieved when PGN was added immediately after viral exposure. Kinetic studies and analysis of HIV DNA products indicated that GC exposure and TLR2 activation enhanced HIV infection at the step of nuclear import. We conclude that GC enhanced HIV infection of primary resting CD4(+) T cells through TLR2 activation, which both increased the susceptibility of primary CD4(+) T cells to HIV infection as well as enhanced HIV-infected CD4(+) T cells at the early stage of HIV life cycle after entry. This study provides a molecular mechanism by which nonulcerative sexually transmitted infections mediate enhancement of HIV infection and has implication for HIV prevention and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147631      PMCID: PMC3739425          DOI: 10.4049/jimmunol.0902125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

Review 1.  Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden.

Authors:  M Stevenson; B Brichacek; N Heinzinger; S Swindells; S Pirruccello; E Janoff; M Emerman
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

2.  Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.

Authors:  M I Bukrinsky; N Sharova; M P Dempsey; T L Stanwick; A G Bukrinskaya; S Haggerty; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

3.  Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men.

Authors:  D W Cameron; J N Simonsen; L J D'Costa; A R Ronald; G M Maitha; M N Gakinya; M Cheang; J O Ndinya-Achola; P Piot; R C Brunham
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

4.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses.

Authors:  B K Chen; K Saksela; R Andino; D Baltimore
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques.

Authors:  P S Polacino; H A Liang; E J Firpo; E A Clark
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

7.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Cofactors in male-female sexual transmission of human immunodeficiency virus type 1.

Authors:  F A Plummer; J N Simonsen; D W Cameron; J O Ndinya-Achola; J K Kreiss; M N Gakinya; P Waiyaki; M Cheang; P Piot; A R Ronald
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

9.  Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation.

Authors:  T Miyazaki; Z J Liu; A Kawahara; Y Minami; K Yamada; Y Tsujimoto; E L Barsoumian; R M Permutter; T Taniguchi
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

10.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.

Authors:  M I Bukrinsky; T L Stanwick; M P Dempsey; M Stevenson
Journal:  Science       Date:  1991-10-18       Impact factor: 63.714

View more
  29 in total

1.  HIV type 1 infection up-regulates TLR2 and TLR4 expression and function in vivo and in vitro.

Authors:  Juan C Hernández; Mario Stevenson; Eicke Latz; Silvio Urcuqui-Inchima
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-12       Impact factor: 2.205

2.  High glucose enhances HIV entry into T cells through upregulation of CXCR4.

Authors:  Xiqian Lan; Kang Cheng; Nirupama Chandel; Rivka Lederman; Aakash Jhaveri; Mohammad Husain; Ashwani Malhotra; Pravin C Singhal
Journal:  J Leukoc Biol       Date:  2013-08-02       Impact factor: 4.962

Review 3.  Clinical parameters essential to methodology and interpretation of mucosal responses.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

Review 4.  Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects.

Authors:  Gary A Jarvis; Theresa L Chang
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

5.  TLR2 activation enhances HIV nuclear import and infection through T cell activation-independent and -dependent pathways.

Authors:  Jian Ding; Theresa L Chang
Journal:  J Immunol       Date:  2011-12-30       Impact factor: 5.422

6.  Lactobacillus crispatus and its enolase and glutamine synthetase influence interactions between Neisseria gonorrhoeae and human epithelial cells.

Authors:  Jagoda Płaczkiewicz; Paulina Chmiel; Ewelina Malinowska; Pawel Bącal; Agnieszka Kwiatek
Journal:  J Microbiol       Date:  2020-04-11       Impact factor: 3.422

7.  Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEK1/2-dependent upregulation of TNF-α and IL-6.

Authors:  Gokul Swaminathan; Daniel Pascual; Germaine Rival; Renzo Perales-Linares; Julio Martin-Garcia; Sonia Navas-Martin
Journal:  FEBS Lett       Date:  2014-08-14       Impact factor: 4.124

8.  A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV.

Authors:  Molly OhAinle; Louisa Helms; Jolien Vermeire; Ferdinand Roesch; Daryl Humes; Ryan Basom; Jeffrey J Delrow; Julie Overbaugh; Michael Emerman
Journal:  Elife       Date:  2018-12-06       Impact factor: 8.140

9.  Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Authors:  Kara Jensen; Myra Grace Dela Pena-Ponce; Michael Piatak; Rebecca Shoemaker; Kelli Oswald; William R Jacobs; Glenn Fennelly; Carissa Lucero; Katie R Mollan; Michael G Hudgens; Angela Amedee; Pamela A Kozlowski; Jacob D Estes; Jeffrey D Lifson; Koen K A Van Rompay; Michelle Larsen; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

10.  Neisseria gonorrhoeae-derived heptose elicits an innate immune response and drives HIV-1 expression.

Authors:  Rebecca J Malott; Bernd O Keller; Ryan G Gaudet; Shannon E McCaw; Christine C L Lai; Wendy N Dobson-Belaire; J Leigh Hobbs; Frank St Michael; Andrew D Cox; Trevor F Moraes; Scott D Gray-Owen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.